Birth weight, infant growth and insulin resistance

Ken K Ong and David B Dunger
Department of Paediatrics, University of Cambridge, Addenbrooke’s Hospital Box 116, Cambridge CB2 2QQ, UK
(Correspondence should be addressed to K K Ong; Email: Ko224@cam.ac.uk)

Abstract
Size at birth and early postnatal growth rates are important determinants of human perinatal survival; they also predict the tempo of growth, adult height and long-term risks for obesity, type 2 diabetes and cardiovascular disease. Results from the Avon Longitudinal Study of Pregnancy and Childhood (ALSPAC) show that fetal growth is influenced by both fetal genes and maternal–uterine–placental factors. Important maternal–placental factors include parity, smoking and weight gain, but also maternal genetic factors in the mother or fetal placenta, including the mitochondrial DNA 16189 variant and H19. These maternal genetic factors particularly influence smaller, growth-restrained infants, as in first pregnancies. Fetal genes include the insulin gene (INS) VNTR (variable number of tandem repeat), which we recently confirmed to be associated with birth size and cord blood IGF-II levels; these fetal gene effects are more evident in the absence of maternal–uterine growth restraint.

During postnatal life, the INS VNTR III/III genotype remains associated with body size, including body mass index and waist circumference, and also lower insulin sensitivity among girls. However, as at birth, significant gene–environment interactions are seen. Rapid ‘catch-up’ early postnatal weight gain follows maternal–uterine restraint, and strongly predicts later childhood obesity and insulin resistance; among these children, those with INS VNTR class I alleles are more obese. Genetic factors that influence early growth may have conferred some early survival advantage in human history during times of undernutrition. With abundant nutrition and rising obesity rates, these genetic factors and their interactions with maternal and childhood environmental factors that influence childhood growth may now contribute to the early development of adult disease risk. Their recognition may help the development of targeted early interventions to prevent the progression towards adult disease.

Introduction
Size at birth and early infancy growth have long been recognised to be important indicators of maternal and offspring health, and of early childhood survival (1, 2). Rapid early weight gain or large size in early childhood has also been linked to earlier sexual maturation (3–5). In recent years, the significance of perinatal and childhood growth patterns has been further extended by studies that show links with much longer term risks of diseases in adult life, such as type 2 diabetes and cardiovascular disease (6, 7). More recent studies, with postnatal growth data, show that the most common growth pattern related to later disease risk is the combination of relatively lower birth weights and subsequently becoming overweight or obese either during childhood or adult life (8, 9). These findings led Hales and Barker to suggest the ‘thrifty phenotype’ hypothesis, where early exposure of the fetus to poor nutrition leads to permanent changes in insulin metabolism and body fat distribution (10, 11).

Size at birth for gestational age is a marker of fetal growth rate; it is influenced by a wide range of factors that act on the maternal–uterine environment, such as maternal parity and smoking during pregnancy, and also by factors that are familial or heritable (12, 13). These inherited and environmental factors may be complexly interrelated. For example, the contribution of parental inheritance to birth weight, as estimated by the strength of correlation between parent and offspring birth weights, is reduced in conditions where fetal growth is restrained, such as by maternal smoking in pregnancy or in first pregnancies (13). Therefore both environmental and genetic factors, and their interactions, may contribute to both fetal and early childhood growth and its links with long-term disease risks.

Size at birth and adult disease risk
The early reports in historical birth cohorts of association between smaller size at birth, and cardiovascular disease and adult onset diabetes, have since been replicated in diverse populations from different countries (14, 15). The findings persist when differences in gestational age are taken into account, and they appear to be independent of selection bias or potential confounding...
factors due to social class or smoking (16). Importantly, the birth weight associations are not confined to differences between the smallest versus the other infants, but rather relate to a continuum of variable risk throughout the whole range of birth weights. For example, the original studies in men born in Hertfordshire, UK between 1911 and 1930 found that those with above average birth weight had 24% lower standardised mortality rates from coronary artery disease compared with those with average birth weights (6). In some populations the birth weight–adult disease association appears to be ‘U-shaped’, with the heaviest-born babies also having an increased long-term risk for disease (17, 18). Recent longitudinal growth data, including early childhood growth, in subjects from Finland who went on to develop type 2 diabetes in adult life showed that both larger and smaller birth weight patterns are associated with increased disease risk (19). It is likely that the long-term disease associations with larger birth weight may reflect the influence of maternal diabetes in promoting both larger birth size and conferring offspring diabetes risk (20).

Epidemiological studies indicate that size at birth and early weight gain predict the long-term risks for obesity and abnormal fat distribution. In a study of 300,000 19-year-old men exposed to the Dutch famine between 1944 and 1945, there was a nearly twofold increase in obesity risk in those subjects whose mothers were exposed to famine during the first trimesters of pregnancy (21). Gale et al. (22) showed that, among 70–75-year-old men studied by dual-energy x-ray absorptiometry scanning, low birth weight was associated with reduced lean tissue mass and greater body fat relative to current weight. The predisposition to adult disease conferred by low birth weight may therefore be related to excess fat deposition, in particular central fat, and the development of insulin resistance. One study, using the gold standard euglycaemic–hyperinsulinaemic clamp assessment of insulin sensitivity in 70-year-old men showed that the association between low birth weight and insulin resistance was only seen in the highest body mass index (BMI) tertile group (23). Thus, it appears to be the transition from relatively lower birth weight to larger postnatal body size that confers disease risk. With increasing abundance of nutrition and rising rates of obesity such transition may occur at younger ages (24, 25), and the effects of these factors (nutrition, obesity and transition) are currently being explored in contemporary birth cohort studies.

Rapid ‘catch-up’ early postnatal weight gain

Growth data from large contemporary birth cohorts, such as the Avon Longitudinal Study of Pregnancy and Childhood (ALSPAC) (26), confirm much earlier observations in smaller studies (27) that around 25% of all newborn infants will show a significant degree of postnatal rapid or ‘catch-up’ growth (28). Such babies tend to be longer at birth with a larger head circumference relative to their birth weight, and therefore show reduced adiposity at birth compared with other babies of the same birth weight. A further 25% of all newborn infants have relatively increased adiposity at birth and will show postnatal slow or ‘catch-down’ growth (28). The remaining infants who do not show postnatal catch-up or catch-down growth are those who grow along the same weight and length centile positions, and appear to more closely follow their genetic growth trajectory from birth as indicated by consistent strength of correlation with their mid-parental target heights (29). Catch-up and catch-down postnatal growth are most marked in terms of changes in adiposity, and are largely seen within the first 12 months of life, although they may take up to 2 years to complete (30).

The large extent of early postnatal catch-up and catch-down growth suggests that wide variations in gains in adiposity may also occur during late pregnancy. In the ALSPAC birth cohort we have shown that early postnatal catch-up and catch-down growth are closely related to maternal factors during pregnancy, such as mother’s pregnancy weight gain, smoking during pregnancy and parity (birth order). The effect of parity is particularly striking in that first babies are more likely to be restrained in utero, are thinner at birth and show early postnatal catch-up growth, whereas offspring of subsequent pregnancies are more likely to show in utero growth enhancement with postnatal catch-down growth (30). There is some evidence to suggest that these postnatal patterns of weight gain are driven by satiety, as indicated by early feeding studies in infants by Ounsted & Sleigh (31), and by the finding of significant relationships between the levels of the satiety hormone leptin in cord blood at birth and subsequent patterns of weight gain (32). By the time early postnatal catch-up and catch-down growth are completed, the infants are closer to their genetic target size, as predicted by their parents’ heights (27, 29). Thus, during the early months of life, when feeding patterns are strongly influenced by the infant, and growth is regulated by nutrition, inherent patterns of increased or decreased appetite and satiety may return the infant towards its genetic growth trajectory.

However, these patterns of early postnatal growth also appear to have more long lasting effects. In the ALSPAC cohort, subjects who showed early catch-up growth became the heaviest of all children at the age of 5 years (28). This excess weight has persisted in ALSPAC catch-up children at their recent 8-year follow-up (Fig. 1), and similar observations have been made in large cohort studies in the US and in the Seychelles (33, 34). In addition to BMI (weight for height), in our studies those ALSPAC children who showed early catch-up growth also had increased abdominal circum-
obesity and disease risk, and that the development of insulin resistance and increased central adiposity may be a very early feature of this growth pattern. These findings are comparable with results generated by animal models where prenatal growth restriction, followed by postnatal ad libitum feeding can result in insulin resistance and diabetes (11).

**Genetic determinants of early growth and adult disease risk**

Gene knock-out animal models have shown that the genes encoding insulin, the insulin-like growth factors (IGF-I and IGF-II), their receptors and regulatory proteins, and the insulin receptor substrate-1 have major effects on fetal growth and size at birth (43–45). Birth weights in mice homozygous for null mutations in either IGF1 or IGF2 were reduced to around 60% compared with wild-type mice (46, 47), and knock-out of the gene encoding the type 1 IGF receptor (Igf1r), which signals the anabolic actions of both IGF-I and IGF-II, resulted in even more severe fetal growth retardation (46). Birth weights 45% of normal (43). In contrast knock-out of Igf2r, which encodes the non-signalling IGF-II/mannose 6-phosphate receptor, resulted in fetal overgrowth (48).

In humans, rare genetic mutations in the genes that influence insulin action, such as the insulin receptor (49) and glucokinase, which regulates fetal insulin secretion, result in small size at birth (50), and underline the importance of insulin in the regulation of human fetal growth (51). Partial IGF1 deletion has been reported in one subject who showed severe intrauterine and postnatal growth failure (52), and recently mutations in IGF1R have been reported in two children who also had retarded intra-uterine and postnatal growth (53). In addition, the Beckwith–Wiedermann fetal overgrowth syndrome has been associated with mutations and genetic variants that lead to IGF2 over-expression (54–56). Common genetic variants in these genes could contribute to variations in birth size, and to their links with long-term disease risks.

Genetic factors could also underlie population differences in risks for obesity-related disease. Although obesity rates have increased dramatically in developed countries and urban populations, the risk of obesity-related disease appears to be disproportionately distributed, with very high rates among subjects from ethnic populations who had experienced poor nutrition until relatively recently in their history (57, 58). Thus, rates of obesity-related type 2 diabetes are particularly high in Native Americans and Hispanics and similar patterns have emerged in Australian aborigines and the Indonesian islanders (58). In children of south Asian descent, the move from rural to urban environments or migration to the US, UK and other European countries has been associated with a greatly increased prevalence of obesity-related disease and, in particular, type 2 diabetes (59). The thrifty genotype hypothesis

Figure 1 Persisting effects of early postnatal catch-up weight gain (gain in weight s.d. score (SDS) between 0 and 3 years greater than 0.67 SDS) on body weight at 5–8 years old. Data from the ALSPAC cohort.
was originally proposed by Neel in 1962 to explain the remarkably high prevalence of type 2 diabetes in recently Westernised, previously undernourished populations (60). He suggested that there may be common genetic polymorphisms which conferred some survival advantage during earlier times of undernutrition, and through the process of selection are now over-represented in certain populations who have adapted to conditions of poor or intermittent nutrient supply.

The original thrifty genotype hypothesis and subsequent debate has been centred on how genetic variations might enhance survival during adult life (61). We would suggest that, in view of the relatively high mortality rates during perinatal life (1), and in particular during times of nutritional debilitation (62), thrifty genotypes that evolved to enhance early perinatal survival may have a larger effect on reproductive fitness and selection advantage than genotypes that promote adult survival. Such ‘fetal thrifty genotypes’ could now underlie current links between birth weight and adult disease risk.

The mean birth weight in any population is always slightly less than the optimal for perinatal survival of the infant (2), and as Moore and Haig (63) pointed out there is a complex paradigm where the interests of the mother may conflict with those of the father over fetal growth rates. Whereas it is in the interests of the father to have a larger baby, which achieves higher rates of perinatal survival and transmission of the father’s genes to subsequent generations, fetal overgrowth may be dangerous to the mother by making greater nutrient demands and by resulting in prolonged or obstructed labour. These conflicting interests of the mother and the father may have underpinned the evolution of genetic imprinting, a mechanism whereby only those genes transmitted from either the mother or the father are expressed, and the others are silenced (64).

A large proportion of those genes that are known to be imprinted are involved in the regulation of fetal growth; in general, genes that are exclusively paternally expressed enhance fetal growth, whereas exclusively maternally expressed genes are associated with reduced fetal growth (63, 65).

In infants who are smaller at birth, such as first-born infants who tend to be relatively restrained in utero, birth weight is more closely related to the birth weight of the mother, and of the offspring of the mother’s female relatives, suggesting a specific maternally linked transmission of genetic factors that restrain fetal growth (66). We have reported genetic associations between size at birth and the mitochondrial DNA 16189 variant (67) which is maternally inherited, and also with a common polymorphism in the maternally expressed H19 gene (68). H19 is a regulator of imprinting of the insulin-like growth factor-2 gene (Igf2), and its deletion in mice results in IGF2 overexpression and larger birth size (69). In the ALSPAC birth cohort, we observed that, particularly among restrained first pregnancies, a common H19 genotype in the mother or offspring was associated with higher cord blood IGF-II protein levels and larger birth size (68).

In average and larger birth weight babies, such as second- and third-born infants where fetal growth restraint is less evident, a more Mendelian pattern of birth weight inheritance is observed (66). In these pregnancies, a variable number of tandem repeat (VNTR) polymorphism adjacent to the insulin gene (INS), which regulates both INS and IGF2 expression (70, 71), has been repeatedly associated with size at birth, in particular with head circumference at birth and also with IGF-II protein levels in cord blood at birth (29, 72). While IGF2 is paternally expressed in most tissues, the birth size association with INS VNTR showed no parent-of-origin effect and class III allele transmission from either parent was significantly associated with larger offspring birth size (Fig. 2). Thus, with regard to human pregnancy, there is some evidence that maternal genes may restrain fetal growth, however the role of exclusively paternally expressed genes in enhancing fetal growth has not yet been demonstrated.

Although we may be able to identify common genetic variations that are associated with size at birth, it is yet to be established whether these are thrifty, or survival-enhancing, genotypes that could underpin future disease risk. The case is strongest for the INS VNTR, as this genetic polymorphism has been associated with postnatal weight gain, insulin resistance, central fat deposition and type 2 diabetes (73–76). One could argue that larger size at birth, conferred by the INS VNTR class III/III genotype, might improve fetal survival, but at the expense of increased subsequent risks for increased central adiposity, insulin resistance and, ultimately, type 2 diabetes. Other genes that promote the development of adiposity during early postnatal life could also have had selective advantages in promoting early survival. The development of central adiposity, although now
linked with disease in today’s overweight populations, could be considered as a survival advantage when nutrition was poor, as this central fat store provides a much more readily accessible source of nutrients during prolonged fasting or starvation compared with other body fat depots (77). These hypotheses relating candidate thrifty genotypes to perinatal survival and long-term disease risks could be studied in African populations where there is considerable genetic diversity (78), and particularly in some rural populations where variable nutrient supply still has an important impact on survival (62).

**Interactions between phenotype, genotype and obesity risk**

Experimental studies exploring the thrifty phenotype hypothesis in animal models have indicated that long-term obesity and disease risk markers can indeed be programmed by alterations in maternal nutrition such as protein restriction (79, 80), or by reduced nutritional supply to the fetus by uterine artery ligation in late pregnancy (81).

However, the implications of these observations that improving maternal nutrition may prevent future disease risk may not be true for humans. In contemporary populations, no clear relationship is seen between decreased maternal food intake and smaller size at birth (82–84), yet 25% of all infants still show fetal growth restriction and postnatal catch-up growth which are known to be risk factors for the development of obesity and insulin resistance. In rural African populations where there is extremely poor maternal nutrition, maternal restraint of fetal growth may be further exaggerated and could contribute to increased long-term disease risks (85). However, even in such populations, although improved maternal nutrition may benefit perinatal survival and reduce disease burden associated with poor nutrition in postnatal life (62), improved nutrition is unlikely to obviate long-term disease risks associated with insulin resistance, as these nutritional changes lead quickly to maternal obesity (86). Maternal weight gain is associated with increased risk for gestational diabetes, and this could underlie the associations between large birth weight and type 2 diabetes risk (20, 87). Thus, against a genetic background that predisposes to obesity and gestational diabetes, the shift from poor to improved maternal nutrition could accelerate type 2 diabetes risk rather than reduce it.

In addition to obesity and type 2 diabetes, the prevalence of polycystic ovary syndrome (PCOS) is also increased in populations where there has been, until recently, relatively poor nutrition (88). PCOS is associated with increased androgen production, which could contribute to increased central adiposity (89), and it is associated with increased risk for type 2 diabetes, and gestational diabetes (90). In UK populations, PCOS is associated with larger birth weight (91, 92), perhaps reflecting the effects of gestational diabetes, or even high-normal glucose levels in the mother.

Genetic factors associated with PCOS include the INS VNTR class III/III genotype (74), and shorter CAG repeat length in the androgen receptor gene which confers greater receptor sensitivity (93). These genetic factors increase insulin resistance and androgen activity and thus may themselves be seen as risk factors for increased central adiposity. Therefore, in populations with a long history of undernutrition, and a possible background genetic predisposition to PCOS, type 2 diabetes and gestational diabetes, a sudden change to abundant nutrition and obesity could rapidly lead to a vicious cycle of increasing childhood weight gain, increased risk of ovarian hyperandrogenism, central adiposity and gestational diabetes, which, in turn, would increase the risk of type 2 diabetes in the next generation.

**Relevance of perinatal factors to the current increase in childhood obesity**

The disease risks associated with obesity are not uniformly distributed (57). Although the numbers of obese children who show impaired glucose tolerance or other risk markers for cardiovascular disease during adolescence may be alarming (94), there are still a large number of overweight or obese children who appear to have a low risk for the development of these diseases, at least in the short term. Increased understanding and more specific prediction in each individual of the disease risks associated with obesity could result from studies of interaction between early environmental and genetic factors, such as between early postnatal weight gain and INS VNTR genotype (72). In the presence of abundant nutrition and reduced energy expenditure, such interactions could determine the site of fat deposition and the associated development of insulin resistance. Furthermore, while insulin resistance may be a major risk factor for cardiovascular disease and type 2 diabetes (95), the ultimate development of type 2 diabetes is determined by the ability of the β cell to sustain compensatory hyperinsulinaemia (96). In recent studies in the ALSPAC birth cohort we were able to show that early weight gain was the major determinant of insulin resistance, however insulin secretion was more closely related to early height gain (41). Thus, an understanding of early growth patterns and their associations with central adiposity and insulin resistance, and how these, in turn, may be modified by the genetic background, will be important in developing appropriate targeted interventions to prevent disease risks associated with obesity during childhood (Fig. 3). Studies that combine early growth patterns and genetic factors to predict obesity and disease risks may also provide an opportunity to apply such targeted interventions at a much earlier stage.
Acknowledgements

We are extremely grateful to the ALSPAC study team, and to all the children and parents who took part. ALSPAC is supported by the Medical Research Council, the Wellcome Trust, the UK Department of Health, the Department of the Environment, the National Institutes of Health, a variety of medical research charities and commercial companies. D B D is supported by the Wellcome Trust and the Juvenile Diabetes Research Foundation.

References

7 Hales CN, Barker DJ, Clark PM, Cox LJ, Fall C, Osmond C & Winter PD. Fetal and infant growth and impaired glucose tolerance at age 64. *British Medical Journal* 1991 303 1019–1022.

Figure 3 Schematic diagram summarising the proposed interaction between fetal thrifty genotypes and fetal growth restraint, resulting in a thrifty phenotype that enhances perinatal survival, postnatal growth and reproductive advantage, but leads to increased risks for disease in adulthood. ‘In the absence of fetal growth restraint and postnatal catch-up growth, the III/III genotype leads to larger size at birth, and postnatal increased adiposity and insulin resistance.'
Birth weight, infant growth and insulin resistance


39 Bauder A, Yajnik CS, Fall CH, Bapat S, Pandit AN, Deshpande V, Bhave S, Kellingray SD & Joglekar C. Insulin resistance syndrome in 8-year-old Indian children: small at birth, big at 8 years, or both? *Diabetes* 1999 48 2422–2429.


44 Liu JP, Baker J, Perkins AS, Robertson El & Elfratidadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). *Cell* 1993 75 59–72.


www.eje.org
gene induces changes in Igf2 methylation in both cis and trans. PNAS 1999 94 10243–10248.
61 Reaven GM. Hypothesis: muscle insulin resistance is the (‘not-so’) thrifty genotype. Diabetologia 1991 34 482–484.
71 Ozanne SE, Lewis R, Jennings BJ & Hales CN. Early programming of weight gain in mice prevents the induction of obesity by a highly palatable diet. Clinical Science 2004 106 141–145.
93 Ibanez L, Ong KK, Mongan N, Jaakkelainen J, Marcos MV, Hughes IA, De Zegher F & Dunger DB. Androgen receptor gene CAG repeat polymorphism in the development of ovarian hyperandrogenism. Journal of Clinical Endocrinology and Metabolism 2003 88 3333–3338.

Received 18 May 2004
Accepted 10 August 2004